European Union - English - EMA (European Medicines Agency)

lipomed gmbh - thalidomide - multiple myeloma - immunosuppressants - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.4).

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - sarilumab (unii: nu90v55f8i) (sarilumab - unii:nu90v55f8i) - sarilumab 150 mg in 1.14 ml - kevzara® is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (dmards). kevzara is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. kevzara is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients [see warnings and precautions (5.5) and adverse reactions (6.1)] . risk summary the limited human data with kevzara in pregnant women are not sufficient to inform drug-associated risk for major birth defects and miscarriage. monoclonal antibodies, such as sarilumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant (see clinical considerations) . from animal data, and consistent with the mechanism of ac

European Union - English - EMA (European Medicines Agency)

lipomed gmbh - deferiprone - iron overload; beta-thalassemia - all other therapeutic products - deferiprone lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.deferiprone lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - gemeprost, quantity: 1 mg - pessary - excipient ingredients: ethanol; hard fat - for the softening and dilatation of the cervix uteri prior to transcervical, intrauterine operative procedures in the first trimester of pregnancy. therapeutic termination of pregnancy in patients in the second trimester of gestation.

Israel - English - Ministry of Health

sanofi israel ltd - sarilumab - solution for injection - sarilumab 131.6 mg / 1 ml - sarilumab - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.

Israel - English - Ministry of Health

sanofi israel ltd - sarilumab - solution for injection - sarilumab 175 mg / 1 ml - sarilumab - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.kevzara is indicated for treatment of adult patients with polymyalgia rheumatica who cannot tolerate corticosteroid taper

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthritis, rheumatoid - immunosuppressants - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

a h pharmaceuticals (ay) - saribadi - liquid

Bangladesh - English - DGDA (Directorate General of Drug Administration)

aci ayurvedic - saribadyarista - liquid

Bangladesh - English - DGDA (Directorate General of Drug Administration)

ayurved kutir ltd - saribadyarista - syrup